Our Setup Worked: +25% Later the Trade Gets More Interesting

Why discipline mattered, what changed since the FDA approval, and how we manage the next phase

Our last deep dive on Novo Nordisk NVO 0.00%↑ came at a very specific moment.

The stock had just reacted to a major FDA approval, sentiment was loud, and price had already jumped. This is usually where mistakes happen. Instead of chasing, we slowed things down.

We focused on execution.

In that note, we laid out a clear framework: where risk actually made sense, where confirmation mattered, and how upside should be managed if the story worked. No hero calls. No hype. Just structure.

Since that publication on Dec 23, 2025, NVO has done the work.

Table of Contents

1. Business Overview

2. Technical Setup

3. Updated Trade Plan

The primary entry zone we highlighted around 50 to 51 was followed by a clean advance into the low 60s. At the recent highs near 62 to 63, that move represents roughly +22% to +25%, depending on execution. The first upside objective near 55.5 was reached quickly, and the extended objective toward the low 60s was hit shortly after

That is exactly how a well-structured plan is supposed to play out.

This was not about predicting headlines. It was about respecting levels, letting the trade come to us, and managing upside without emotion.

This update is about what comes next.

We will walk through what has changed in the business since that FDA approval, how those changes affect the long-term setup, what the technical picture is telling us now, and how we are thinking about positioning from here, both for existing holders and for those still waiting for a cleaner entry.

If you followed the original plan, you are not chasing strength.
You are managing a winner.

Key takeaways

• Our last NVO plan worked because it focused on structure, not hype. Defined risk near 50 led to a move into the low 60s.

• The business story strengthened after FDA approval. Oral Wegovy shifts the focus from demand to execution and scale.

• The recent pullback from 62.33 to the high 50s is normal after a fast rally and is a test, not a breakdown.

• The 58.8 to 58.2 zone is the first area where buyers need to show up to keep momentum intact.

• A deeper pullback into 56.7 to 55.1 would still be bullish, but patience becomes more important.

• A reclaim and hold above 62.3 to 62.9 opens the door to the next upside leg.

• Upside checkpoints remain 64.7, 66.5 to 67.6, then 70.3 to 74.2 if strength builds.

• Below 55.1, the post approval structure weakens and risk needs to be reassessed.

• The edge here is discipline. Buy dips with defined risk or buy breakouts only after confirmation.

Business updates since our last note and why they matter

When we wrote our last piece on Novo Nordisk, the key shift was clear: FDA approval for oral Wegovy moved the story from promise to execution. Since then, the market has started to focus less on the headline and more on how well Novo can actually deliver.

Here is what changed, and more importantly, why it matters.

Oral Wegovy moved from approval to real-world rollout

The biggest development is not new approvals. It is traction.

Oral Wegovy is now broadly available in the US. Early prescription data and channel checks suggest demand is strong, especially among patients who delayed treatment due to injections. This matters because pills widen the funnel. More patients can start earlier, stay on therapy longer, and move through the system with less friction.

The key insight here is not volume alone. It is duration. Longer treatment cycles matter more than one-time starts. That is where lifetime value compounds.

This directly supports the thesis we outlined before: oral access does not replace injections, it expands the total pie.

Supply pressure eased, which quietly strengthens the story

One major shift since our last post is that semaglutide shortages have eased. This is not flashy, but it is important.

When supply is tight, growth is capped no matter how strong demand is. With supply improving, Novo gains three things:

• Better patient retention

• Fewer forced switches or drop-offs

• More leverage in payer discussions

It also weakens the gray market and compounded alternatives that thrived during shortages. That is a long-term positive for brand control and pricing power.

Regulatory noise cooled down

Another subtle but meaningful change: regulators have stepped back from some of the more alarming language around GLP-1 safety, including mental health related warnings.

This does not suddenly make the drugs risk-free. But it reduces headline risk. Fewer scary narratives means fewer reasons for payers and doctors to hesitate. That helps adoption at the margin, especially in primary care.

The pipeline narrative shifted from defense to offense

Novo is no longer just defending share against competitors. The company is actively building the next cycle.

CagriSema continues to move forward as a higher-impact obesity option, and amycretin reinforces that Novo is serious about combination therapies, not just single-drug extensions.

The insight here is timing. Novo is layering new products before competition fully catches up. That keeps them in control of the market conversation instead of reacting to it.

Competition is real, but the gap is not closing yet

Yes, competition is increasing. That was never in doubt. But execution still favors Novo.

They have scale, manufacturing depth, regulatory experience, and now multiple delivery formats. Most competitors still have one or two shots on goal. Novo has a portfolio.

The market is starting to price this in. That is why the stock stopped trading like a broken growth name and started trading like a business with staying power.

Business takeaway

Nothing since our last post broke the thesis. In fact, most developments reinforced it.

The story has shifted from “this could be big” to “show us how well you can run it.” Novo is doing that step by step.

That is why price held gains instead of giving them back.

Technical Setup

Let’s talk about what NVO is doing right now, without getting hypnotized by green candles.

The big picture: this is a rebound that turned into a trend attempt

The weekly chart tells the story in one sentence: NVO stopped bleeding, built a base, then broke out.

The key pivot was the 43.08 low. From there, the stock worked higher and recently tagged the prior swing high zone around 62.32 to 62.33.

That matters because 62.32 is not a random number. It is the point where the rebound stops being “a bounce” and starts being “a new trend”, because you are taking out the prior ceiling.

Why the low 60s are tough

This is the part most people ignore.

The low 60s are where:

• late sellers from the downtrend finally feel relief and want out

• early buyers want to lock gains

• momentum traders show up late

So even if the long-term story is strong, the tape often needs to pause here.

That is also why our extension map is so clean:

• 62.32 is the “line in the sand” high

• the next upside checkpoints are 67.55, 70.29, 74.21

Those are not just targets. They are places where the market often says, “Ok, prove it again.”

Daily trend is bullish, but stretched

On the daily chart, the trend is real:

• Price is above the key averages, with the 20 day near 55.51 and the 50 day near 53.12

• That means the rally is not floating on air. It has structure underneath it.

But it is also stretched:

• Daily RSI is around 73, which is hot

• Price is pressing the upper Bollinger area, with the upper band around 62.91

What does that usually lead to?

Not a crash. A breath.

Strong stocks often cool off by moving sideways or pulling back just enough to reset momentum, then push again.

The 4H chart is already doing that cooling for us

This is the part I like most.

While the daily looks excited, the 4H already started to cool:

• 4H RSI is around 53, down from the hotter zone

• Price is still above the rising averages, with the 4H 20 EMA around 59.33

That combo usually means the market is trying to shift from “fast move” to “controlled move.” That is how breakouts survive.

Ichimoku confirms the character change

The daily Ichimoku view is simple:

• Price pushed above the cloud, then held above key lines

• Tenkan is up near 59.21

• Kijun is down near 54.72

  

Momentum is strong, and dips have room to pull back without breaking the trend. This supports a “buy dips, not rips” approach.

The levels that matter

• 62.3 to 62.9 This is breakout pressure. If price holds above it after a pullback, the move is real. If it keeps rejecting, expect chop.

• 60.4 First shallow support. This is where strong trends often bounce quickly.

• 58.2 This is the “keep it bullish” zone. Lose this and the move becomes slower and more painful.

• 56.5 to 55.1 This is the “trend proof” zone. If the stock holds here and starts turning up, the next push has a real base.

• 48.6 This was the invalidation level we laid out in the original plan. If NVO ever loses this on a sustained basis, the entire post approval structure is broken.

Technical takeaway

NVO is bullish on the daily and weekly, but the stock is also arriving at a natural “decision zone” in the low 60s.

The smart money question is not “is this bullish?”

It is: can it digest gains without giving back the base?

If it does, the next targets above are 67.6 then 70.3 then 74.2. If it cannot, the pullback zones at 57.9, 56.5, 55.1 become the real test.

Our Updated Trade Plan

The premarket pullback changes the path, not the thesis.

It tells us the market is digesting gains, not abandoning the move. That is healthy, especially after a fast run into prior supply.

A) For existing holders

If you followed the original plan, nothing here should feel dramatic. This is management, not reaction.

1) Immediate pullback framework (what matters now)

With price trading around 59.7 to 60.0 premarket, we are already testing the first support band.

Here is the pullback ladder that matters:

• 60.4 to 59.8 This is the first shallow reset zone. Holding this area keeps the breakout very clean and keeps momentum traders engaged.

• 58.8 to 58.2 This is the key support zone. If buyers defend this area, it confirms the move is transitioning from impulse to consolidation, not reversal.

• 56.7 to 55.1 This is the deeper but still bullish reset. A pullback here would feel uncomfortable, but it would still preserve the broader breakout structure.

As long as 55.1 holds on a closing basis, the post approval structure remains intact.

2) How to manage upside from here

Because supply showed up in the low 60s, upside needs to be earned again.

Breakout levels to watch after the pullback:

• 62.3 to 62.9 This is the reclaim zone. A strong hold back above this area tells you the pullback did its job.

• 64.7 First upside checkpoint. Expect pauses here. Trimming a small portion is sensible.

• 66.5 to 67.6 Primary upside target band. This is where rallies often slow again.

• 70.3 to 74.2 Stretch zone. If price gets here, this is no longer about belief. It is about execution.

Bottom line for holders: As long as 58.2 to 55.1 holds, the trend is not broken. Below 56.7, tighten risk. Below 55.1, reassess.

B) For people who do not hold

This is where the premarket move actually helps.

Instead of chasing 62, you now get structure.

You have two valid paths.

Option 1: Buy the pullback (preferred if volatility stays elevated)

Ideal pullback zones:

• 58.8 to 58.2 This is the highest-quality dip zone. Risk is defined, and you are closer to where buyers should show up.

• 56.7 to 55.1 This is the secondary zone if the pullback deepens. Still bullish, but patience is required.

Risk reference: Sustained acceptance below 53.5 would invalidate the bullish reset and turn this into a range again.

Option 2: Buy the breakout confirmation

If price stabilizes and turns back up:

• Entry on a sustained reclaim above 62.3 to 62.9

• This confirms that sellers in the prior high zone have been absorbed

Risk reference: Failure back below 60.4 after reclaim would be a red flag

Upside targets remain: 64.7 | 66.5 to 67.6 | 70.3 to 74.2

The key insight

This pullback is not a problem. It is the test.

Strong trends do not go straight up. They pull back, shake weak hands, and then show you who is actually in control.

Right now, NVO is answering one simple question:

Can it hold gains above the high 50s? If the answer is yes, the next leg higher stays very much in play.

Bottom line

Our last NVO note was about one thing: letting a real catalyst meet a real plan. That combination worked.

The stock respected the levels, delivered a move into the low 60s, and is now doing the normal, healthy work of giving some of that move back. That does not weaken the story. It tests it.

As long as NVO holds the high 50s, this remains a bullish, buy the dip structure, not a failed breakout. Above 62.3, momentum reopens. Below 55.1, patience replaces aggression.

Nothing here requires guessing. The business is executing, the chart is structured, and the trade still has clear rules.

That is the edge.

We do not predict. We prepare.

This content is for informational and educational purposes only and reflects our views at the time of writing. It is not investment advice, a recommendation, or an offer to buy or sell any security. All investments involve risk, and prices can move against you. Past performance does not guarantee future results.